Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Invivyd, Inc.
  6. Summary
    IVVD   US00534A1025

INVIVYD, INC.

(IVVD)
  Report
Delayed Nasdaq  -  04:00 2022-11-29 pm EST
2.190 USD   +2.82%
11/17Invivyd Says it Teamed Up With Population Health Partners to Accelerate Clinical Development Projects
MT
11/17Invivyd, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Days
:
Hours
:
Minutes
:
Seconds
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/22/2022 11/23/2022 11/25/2022 11/28/2022 11/29/2022 Date
2.28(c) 2.26(c) 2.14(c) 2.13(c) 2.19 Last
425 531 279 514 183 853 276 102 147 235 Volume
+0.88% -0.88% -5.31% -0.47% +2.82% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -236 M - -
Net cash position 2022 381 M - -
P/E ratio 2022 -1,01x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -208 M - -
Net cash position 2023 175 M - -
P/E ratio 2023 -1,25x
Yield 2023 -
Capitalization 239 M 239 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 102
Free-Float 72,5%
More Financials
Company
Invivyd, Inc., formerly Adagio Therapeutics, Inc., is a biopharmaceutical company. The company is engaged in developing antibodies to transcend the limits of naturally occurring immunity and provide protection from viral diseases, beginning with COVID-19. Its technology works at the intersection of virology, predictive modeling, and antibody engineering. Its platform approach yields a pipeline of engineered... 
More about the company
Ratings of Invivyd, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about INVIVYD, INC.
11/17Invivyd Says it Teamed Up With Population Health Partners to Accelerate Clinical Develo..
MT
11/17Invivyd, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Se..
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
GL
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
CI
11/10INVIVYD, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/10Transcript : Invivyd, Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/10Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
GL
11/09Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
GL
11/09Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
AQ
11/02Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial ..
AQ
10/24Invivyd, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure, Finan..
AQ
10/24Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors
GL
10/24Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors
AQ
More news
News in other languages on INVIVYD, INC.
11/17Invivyd déclare avoir fait équipe avec Population Health Partners pour accélérer les pr..
11/17Invivyd annonce un partenariat avec Population Health Partners pour accélérer le dévelo..
11/10Invivyd, Inc. annonce ses résultats financiers pour le troisième trimestre et les neuf ..
10/24Invivyd annonce des changements au conseil d'administration
10/13Invivyd élimine certains postes dans le cadre d'un " réalignement des ressources " - Le..
More news
Analyst Recommendations on INVIVYD, INC.
More recommendations
ETFs positioned on INVIVYD, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Virtus LifeSci Biotech Clinical Trials ETF - USD0.72%-0.30%United_States
ETFMG Treatments Testing and Advancements E...0.42%-1.57%-NC
ALPS Medical Breakthroughs ETF - USD0.22%0.28%United_States
IShares Micro-Cap ETF - USD0.04%0.71%United_States
Vanguard Russell 2000 Value ETF - USD0.01%-0.93%United_States
More ETFs positioned on INVIVYD, INC.
Chart INVIVYD, INC.
Duration : Period :
Invivyd, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVIVYD, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 2,19 $
Average target price 3,83 $
Spread / Average Target 75,0%
EPS Revisions
Managers and Directors
David Hering Chief Executive Officer & Director
Frederick W. Driscoll Chief Financial & Accounting Officer
Marc W. Elia Chairman
Laura Walker Chief Scientific Officer
Rebecca L. Dabora Chief Technology & Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
INVIVYD, INC.-70.66%232
VERTEX PHARMACEUTICALS43.58%80 935
REGENERON PHARMACEUTICALS, INC.16.58%79 191
BIONTECH SE-37.36%39 245
WUXI APPTEC CO., LTD.-34.05%30 708
GENMAB A/S22.93%29 471